Indian Pharma Surpasses US with 752 FDA-Registered Plants Driving Global Expansion

The Indian pharmaceutical industry is making significant strides on the global stage, having overtaken U.S. counterparts with 752 FDA-registered manufacturing sites. This remarkable achievement is highlighted in a recent McKinsey & Company report, which underscores the industry's commitment to expanding its infrastructure and operations to meet international standards.

As Indian companies diversify their revenue streams, they are witnessing exports grow at a 9% rate, outpacing the global average. To ensure operational continuity and seize emerging opportunities, these firms are investing heavily in infrastructure that adheres to global regulatory requirements. Currently, India boasts 2,050 WHO GMP-certified facilities and 286 EDQM-approved sites, showcasing its robust manufacturing capabilities.

The report also reveals a substantial improvement in compliance, with the number of Official Action Indicated (OAI) notices from the FDA dropping by 50% from 2013 to 2024. Similarly, non-compliance cases from the European Medicines Agency (EMA) have decreased by 27% during this period. With manufacturing costs in India remaining 30-35% lower than in the U.S. and Europe, the country is positioned as a competitive player in the global market.

India is also recognized for having the largest number of Fourth Industrial Revolution (4IR) Lighthouses, reflecting its adoption of advanced automation and digital technologies. The leading Contract Development and Manufacturing Organizations (CDMOs) have collectively invested $650 million to enhance their capabilities, further solidifying India's role in the global pharmaceutical supply chain.

Despite these successes, challenges remain, including geopolitical uncertainties and the rise of nearshoring. To navigate these hurdles, the report advises Indian pharma companies to focus on expanding into the large-molecule segment and enhancing Active Pharmaceutical Ingredient (API) manufacturing.

As India continues to fulfill 20% of global demand for generic medicines and over 40% of U.S. generic drug needs, its strategic investments in infrastructure and operations will undoubtedly shape the future of the pharmaceutical landscape.